Enzyme, Receptor

Enzymes and Receptors are the two most prominent classes of biological molecules that serve as targets for therapeutic intervention. Enzymes act as biological catalysts that facilitate essential biochemical reactions, such as phosphorylation by kinases or proteolysis by proteases, and are frequently targeted by small-molecule inhibitors to disrupt disease-related pathways (Source: Hopkins & Groom, Nature Reviews Drug Discovery, 2002). Receptors are protein structures, typically embedded in the plasma membrane or located within the nucleus, that bind specific signaling molecules to trigger cellular responses; major families include G protein-coupled receptors (GPCRs) and ligand-gated ion channels (Source: Overington et al., Nature Reviews Drug Discovery, 2006). Because the term "Enzymes, Receptors" describes broad functional categories rather than a specific molecular entity, it is not considered a single therapeutic target in drug discovery. Instead, drug development focuses on specific members of these classes, such as Angiotensin-converting enzyme (ACE) or the Beta-1 adrenergic receptor, to achieve therapeutic efficacy while minimizing off-target effects (Source: Santos et al., Nature Reviews Drug Discovery, 2017). Understanding the distinct mechanisms of action—inhibition for enzymes and agonism/antagonism for receptors—is fundamental to pharmacological science (Source: Rang & Dale's Pharmacology, 2019). These classes account for the majority of FDA-approved drugs, with GPCRs alone representing approximately 34% of all marketed medicines (Source: Hauser et al., Nature Reviews Drug Discovery, 2017).

Other names

Biological catalystsCellular receptorsDrug targetsProteins

Enzymes are typically modulated via inhibition (competitive or allosteric) or activation, while receptors are modulated via agonism, antagonism, or inverse agonism (Source: Rang & Dale's Pharmacology, 2019).